Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Swidnica – page 33

985 clinical trials in Swidnica, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Swidnica at a glance
985
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

985 trials in Swidnica

Open in trial search

Seasonal allergy

Not yet recruiting

Study to Find the Best Dose of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis, with or without Asthma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Probelte Pharma S.L.

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Leiomyosarcoma+5

Not yet recruiting

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Intensity Therapeutics Inc.

Study on Gene Therapy for Patients with RAG1-Deficient Severe Combined Immunodeficiency Using RAG1-LV-CD34+ Cells

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Sponsor:Videja B.V.

Anaemia of chronic disease

Not yet recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Darbepoetin Alfa
  • Sponsor:Genexine Inc.

Dermatitis atopic

Not yet recruiting

Study on Eblasakimab for Adults with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Aslan Pharmaceuticals Pte Ltd

Malignant peritoneal neoplasm+2

Not yet recruiting

Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Agencja Badań Medycznych

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not yet recruiting

Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not yet recruiting

Study on Doravirine and Islatravir for People with HIV-1 Previously Treated with the Same Drug Combination

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Swidnica

What the registry says about research in the country

01 Inflammatory Conditions

Innovative research focusing on inflammatory disorders, including trials evaluating new treatments for psoriatic arthritis and rheumatoid arthritis. Studies aim to assess novel therapeutic approaches using biologics and targeted medications.

  • Psoriatic Arthritis Studies
  • Rheumatoid Arthritis Treatment
  • Inflammatory Disease Management

Advanced therapies being tested to improve patient outcomes and quality of life.

02 Gastrointestinal Research

Comprehensive studies investigating treatments for inflammatory bowel diseases, including trials for Crohn's Disease and ulcerative colitis. Research focuses on novel therapeutic agents and long-term disease management.

  • Crohn's Disease Therapies
  • Ulcerative Colitis Treatments
  • Long-term Disease Management

Multiple trials exploring innovative approaches to treating gastrointestinal conditions.

03 Metabolic and Pain Management

Studies addressing obesity, knee osteoarthritis, and chronic pain conditions. Research includes evaluation of new medications for weight management and innovative approaches to pain relief.

  • Weight Management Therapies
  • Osteoarthritis Treatment
  • Pain Management Solutions

Cutting-edge research combining multiple therapeutic approaches for complex conditions.

04 Specialty Conditions

Focused research on unique conditions including thyroid eye disease, chronic spontaneous urticaria, and rotator cuff tendinopathy. Studies aim to develop targeted treatments for these specific medical needs.

  • Endocrine Disorders
  • Autoimmune Conditions
  • Musculoskeletal Treatments

Specialized therapeutic approaches for distinct medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.